SG10201804305SA - Stabilized ophthalmic galactomannan formulations - Google Patents
Stabilized ophthalmic galactomannan formulationsInfo
- Publication number
- SG10201804305SA SG10201804305SA SG10201804305SA SG10201804305SA SG10201804305SA SG 10201804305S A SG10201804305S A SG 10201804305SA SG 10201804305S A SG10201804305S A SG 10201804305SA SG 10201804305S A SG10201804305S A SG 10201804305SA SG 10201804305S A SG10201804305S A SG 10201804305SA
- Authority
- SG
- Singapore
- Prior art keywords
- formulations
- stabilized ophthalmic
- stabilized
- ophthalmic
- guar
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 title abstract 6
- 229920000926 Galactomannan Polymers 0.000 title abstract 3
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 title abstract 2
- -1 hydroxypropyl Chemical group 0.000 abstract 3
- 244000007835 Cyamopsis tetragonoloba Species 0.000 abstract 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 abstract 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 abstract 1
- 239000004327 boric acid Substances 0.000 abstract 1
- 150000002009 diols Chemical class 0.000 abstract 1
- 238000012377 drug delivery Methods 0.000 abstract 1
- 229910001629 magnesium chloride Inorganic materials 0.000 abstract 1
- 239000000600 sorbitol Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Stabilized Ophthalmic Galactomannan Formulations The present invention relates to viscosity stabilized ophthalmic formulations and ophthalmic formulations suitable for drug delivery. The formulations comprise 5 galactomannans such as guar or hydroxypropyl guar and a borate source such as boric acid. The formulations further comprise a diol alcohol such as sorbitol and, optionally, a pharmaceutically acceptable divalent cation salt such as magnesium chloride. 10 (No suitable figure)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33151110P | 2010-05-05 | 2010-05-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201804305SA true SG10201804305SA (en) | 2018-06-28 |
Family
ID=44626461
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2012081386A SG185422A1 (en) | 2010-05-05 | 2011-05-04 | Stabilized ophthalmic galactomannan formulations |
| SG10201804305SA SG10201804305SA (en) | 2010-05-05 | 2011-05-04 | Stabilized ophthalmic galactomannan formulations |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2012081386A SG185422A1 (en) | 2010-05-05 | 2011-05-04 | Stabilized ophthalmic galactomannan formulations |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20110275593A1 (en) |
| EP (1) | EP2566447B1 (en) |
| JP (1) | JP5794744B2 (en) |
| KR (2) | KR20180001587A (en) |
| CN (2) | CN102939074A (en) |
| AR (1) | AR081015A1 (en) |
| AU (1) | AU2011248129B2 (en) |
| BR (1) | BR112012028308B1 (en) |
| CA (1) | CA2798069C (en) |
| ES (1) | ES2809304T3 (en) |
| MX (1) | MX2012012826A (en) |
| NZ (1) | NZ603345A (en) |
| SG (2) | SG185422A1 (en) |
| TW (1) | TWI606841B (en) |
| WO (1) | WO2011140203A2 (en) |
| ZA (1) | ZA201208199B (en) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR071834A1 (en) * | 2008-04-26 | 2010-07-21 | Alcon Res Ltd | POLYMER SYSTEM OF ARTIFICIAL TEARS |
| TWI492769B (en) * | 2009-09-23 | 2015-07-21 | Alcon Res Ltd | Injectable aqueous ophthalmic composition and method of use therefor |
| TW201336527A (en) * | 2012-02-10 | 2013-09-16 | Alcon Res Ltd | Aqueous pharmaceutical composition with enhanced stability |
| UA113434C2 (en) * | 2012-05-04 | 2017-01-25 | Алкон Рісерч, Лтд. | OPHTHALMOLOGICAL COMPOSITION WITH IMPROVED PROTECTION AGAINST DEHYDRATION AND KEEPING |
| ES2908479T3 (en) | 2015-08-26 | 2022-04-29 | Achillion Pharmaceuticals Inc | Compounds for the treatment of immune and inflammatory disorders |
| AR106018A1 (en) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | ARYL, HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS |
| SG11201811491YA (en) | 2016-06-27 | 2019-01-30 | Achillion Pharmaceuticals Inc | Quinazoline and indole compounds to treat medical disorders |
| US11583496B2 (en) | 2016-10-12 | 2023-02-21 | PS Therapy Inc. | Drug vehicle compositions and methods of use thereof |
| EP4241759A1 (en) * | 2016-10-12 | 2023-09-13 | PS Therapy, Inc. | Artificial tear, contact lens and drug vehicle compositions and methods of use thereof |
| US11260035B2 (en) | 2016-10-12 | 2022-03-01 | Ps Therapies Ltd | Topical compositions and methods of use thereof |
| KR102632860B1 (en) | 2017-03-01 | 2024-02-02 | 아칠리온 파르마세우티칼스 인코포레이티드 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for the treatment of medical disorders |
| WO2020041301A1 (en) | 2018-08-20 | 2020-02-27 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement factor d medical disorders |
| EP3846803A4 (en) | 2018-09-06 | 2022-08-10 | Achillion Pharmaceuticals, Inc. | MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISEASES |
| WO2020081723A1 (en) | 2018-10-16 | 2020-04-23 | Georgia State University Research Foundation, Inc. | Carbon monoxide prodrugs for the treatment of medical disorders |
| TWI757773B (en) * | 2019-06-28 | 2022-03-11 | 瑞士商愛爾康公司 | Ophthalmic compositions |
| EP4107166A4 (en) | 2020-02-20 | 2024-06-26 | Achillion Pharmaceuticals, Inc. | Heteroaryl compounds for treatment of complement factor d mediated disorders |
| JP7787164B2 (en) | 2020-09-23 | 2025-12-16 | アキリオン ファーマシューティカルズ， インコーポレーテッド | Pharmaceutical compounds for the treatment of complement-mediated disorders |
| US20250276007A1 (en) | 2024-03-04 | 2025-09-04 | Alcon Inc. | Carbamoylphenylboronic acid-containing acrylic monomers and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8028A (en) * | 1851-04-08 | Hokse-poweb | ||
| US4136173A (en) * | 1977-01-31 | 1979-01-23 | American Home Products Corp. | Mixed xanthan gum and locust beam gum therapeutic compositions |
| DE3827561C1 (en) * | 1988-08-13 | 1989-12-28 | Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De | |
| US5505953A (en) * | 1992-05-06 | 1996-04-09 | Alcon Laboratories, Inc. | Use of borate-polyol complexes in ophthalmic compositions |
| DK1348427T3 (en) * | 1997-07-29 | 2008-06-30 | Alcon Lab Inc | Ophthalmic compositions containing galactomannan polymers and borates |
| GB9808461D0 (en) * | 1998-04-22 | 1998-06-17 | Innovative Tech Ltd | Solid borate-diol interaction products |
| US7084130B2 (en) * | 2001-12-11 | 2006-08-01 | Alcon, Inc. | Intraocular irrigating solution having improved flow characteristics |
| TWI336257B (en) * | 2003-06-13 | 2011-01-21 | Alcon Inc | Ophthalmic compositions containing a synergistic combination of three polymers |
| US20100021561A1 (en) * | 2006-09-21 | 2010-01-28 | Chowhan Masood A | Self-preserved aqueous pharmaceutical compositions |
| TWI434926B (en) | 2006-12-11 | 2014-04-21 | Alcon Res Ltd | Use of peo-pbo block copolymers in ophthalmic compositions |
| TW200904485A (en) * | 2007-05-18 | 2009-02-01 | Alcon Res Ltd | Phospholipid compositions for contact lens care and preservation of pharmaceutical compositions |
| AR071834A1 (en) * | 2008-04-26 | 2010-07-21 | Alcon Res Ltd | POLYMER SYSTEM OF ARTIFICIAL TEARS |
| JP2012516936A (en) | 2009-02-05 | 2012-07-26 | アルコン リサーチ， リミテッド | Process for refining guar |
-
2011
- 2011-05-04 MX MX2012012826A patent/MX2012012826A/en active IP Right Grant
- 2011-05-04 TW TW100115587A patent/TWI606841B/en active
- 2011-05-04 CA CA2798069A patent/CA2798069C/en active Active
- 2011-05-04 EP EP11720357.0A patent/EP2566447B1/en active Active
- 2011-05-04 SG SG2012081386A patent/SG185422A1/en unknown
- 2011-05-04 AU AU2011248129A patent/AU2011248129B2/en active Active
- 2011-05-04 US US13/100,439 patent/US20110275593A1/en not_active Abandoned
- 2011-05-04 KR KR1020177037138A patent/KR20180001587A/en not_active Ceased
- 2011-05-04 NZ NZ603345A patent/NZ603345A/en not_active IP Right Cessation
- 2011-05-04 KR KR1020127031590A patent/KR20130060228A/en not_active Ceased
- 2011-05-04 CN CN2011800292803A patent/CN102939074A/en active Pending
- 2011-05-04 BR BR112012028308-1A patent/BR112012028308B1/en active IP Right Grant
- 2011-05-04 JP JP2013509217A patent/JP5794744B2/en active Active
- 2011-05-04 CN CN201610986410.7A patent/CN106389325A/en active Pending
- 2011-05-04 ES ES11720357T patent/ES2809304T3/en active Active
- 2011-05-04 WO PCT/US2011/035165 patent/WO2011140203A2/en not_active Ceased
- 2011-05-04 SG SG10201804305SA patent/SG10201804305SA/en unknown
- 2011-05-05 AR ARP110101556A patent/AR081015A1/en unknown
-
2012
- 2012-10-31 ZA ZA2012/08199A patent/ZA201208199B/en unknown
-
2013
- 2013-05-13 US US13/892,429 patent/US8846641B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| SG185422A1 (en) | 2012-12-28 |
| US20110275593A1 (en) | 2011-11-10 |
| TW201141524A (en) | 2011-12-01 |
| CA2798069A1 (en) | 2011-11-10 |
| KR20130060228A (en) | 2013-06-07 |
| WO2011140203A2 (en) | 2011-11-10 |
| EP2566447B1 (en) | 2020-07-15 |
| CA2798069C (en) | 2016-07-05 |
| MX2012012826A (en) | 2013-01-28 |
| AU2011248129B2 (en) | 2014-10-09 |
| AR081015A1 (en) | 2012-05-30 |
| WO2011140203A3 (en) | 2012-04-19 |
| NZ603345A (en) | 2014-12-24 |
| US8846641B2 (en) | 2014-09-30 |
| ES2809304T3 (en) | 2021-03-03 |
| ZA201208199B (en) | 2014-01-29 |
| EP2566447A2 (en) | 2013-03-13 |
| BR112012028308A2 (en) | 2016-11-01 |
| AU2011248129A1 (en) | 2012-11-29 |
| US20130244971A1 (en) | 2013-09-19 |
| TWI606841B (en) | 2017-12-01 |
| JP5794744B2 (en) | 2015-10-14 |
| KR20180001587A (en) | 2018-01-04 |
| JP2013525493A (en) | 2013-06-20 |
| CN106389325A (en) | 2017-02-15 |
| BR112012028308B1 (en) | 2021-09-28 |
| CN102939074A (en) | 2013-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201804305SA (en) | Stabilized ophthalmic galactomannan formulations | |
| MX2013002422A (en) | Salts of lorcaserin with optically active acids. | |
| MX2014009757A (en) | Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy. | |
| AR112286A2 (en) | POLYMERIC SYSTEM OF ARTIFICIAL TEARS | |
| PH12013501136A1 (en) | Lysophosphatidic acid receptor antagonists and uses thereof | |
| IN2014MN02248A (en) | ||
| MX2013001677A (en) | Stable formulations of linaclotide. | |
| EA033171B1 (en) | Semisolid aqueous pharmaceutical composition containing tapentadol | |
| TN2012000371A1 (en) | Pyrazole compounds as crth2 antagonists | |
| MX345404B (en) | Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-(4-m ethylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactate monohydrate. | |
| TN2012000261A1 (en) | Aerosol formulation for copd | |
| PH12015501377A1 (en) | Solid unit with high fexofenadine content and process for the preparation thereof | |
| MX2012006265A (en) | Hypersulfated disaccharide formulations. | |
| MX2014004210A (en) | 2-oxo-piperidinyl derivatives. | |
| WO2011076840A3 (en) | Aerosol formulation for copd | |
| MX2015007794A (en) | Oral transmucosal delivery of glatiramer acetate. | |
| TW200718698A (en) | Process for preparing new tiotropium salts, new tiotropium salts as such and pharmaceutical compositions thereof | |
| BR112012020828A2 (en) | pharmaceutical preparation containing miramistin | |
| WO2013083226A8 (en) | Anhydrous sodium carbonate with few pores | |
| WO2009121946A3 (en) | Process for the preparation of optically enriched clopidogrel | |
| TR201105424A2 (en) | A pharmaceutical formulation with zinc active ingredient. | |
| WO2012108794A3 (en) | 1,2,4-triazol-3-ylthioglycolic acid derivatives for use in therapy | |
| IN2013DE00880A (en) | ||
| CO7141425A2 (en) | Ophthalmic compositions with improved retention and drying protection | |
| UA78605U (en) | Pharmaceutical composition |